Anti-atheroslerotic drugs, such as rosuvastatin, simvastatin, and lovastatin, can inhibit YAP/TAZ activation to ameliorate the occurrence and development of cardiovascular diseases (29, 31, 50, 51). Here, YAP1 is linked to cardiovascular disorder.